A widely prescribed medication for type 2 diabetes could offer an unexpected defense against cognitive decline. According to a long-term study published in New Scientist, taking the affordable drug metformin may cut a person's risk of developing dementia by roughly half compared to other standard diabetes prevention strategies.
The findings stem from more than two decades of follow-up data from the Diabetes Prevention Program, a clinical trial initiated in the 1990s. Researchers tracked health outcomes across three distinct groups: participants assigned to take metformin, those enrolled in an intensive lifestyle program focused on diet and exercise, and a control group receiving a placebo.
Over the long tracking period, only 1.9 percent of participants in the metformin group developed dementia. In contrast, dementia was diagnosed in 4.2 percent of the lifestyle intervention group and 3.5 percent of the placebo group. The substantial gap suggests that metformin may provide protective benefits to brain cells beyond its known role in regulating blood sugar.
While medical researchers view the data as promising, they emphasize that the results are not yet definitive. Dr. José Luchsinger of Columbia University noted that while the study offers some of the strongest evidence available short of a dedicated dementia trial, the underlying biological mechanism remains unclear.
Because metformin has been safely used for decades and is available cheaply as a generic drug, confirming its protective qualities could offer a simple, accessible tool in the global fight against dementia.